CHENGDU, China, April 24, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) was invited to attend the 2014 Guosen Securities Investment Conference for Overseas Listed Chinese Healthcare Companies that was held at Shenzhen Marco Polo Hotel on 22nd of April, 2014.
Dr. James J. Tong, CFO and Director of TPI presented the Company from 4:20pm to 5:30pm at the conference. The power point presentation is available for downloading at www.tianyinpharma.com or by request to ir@tpi.asia
About Guosen Securities
Guosen Securities Company Limited ("Guosen Securities" or "GSEC") is a Chinese state-owned financial services company headquartered in Shenzhen, China, with more than 70 branches and 11,500 employees nationwide. It has offices in 47 major cities in China including Shenzhen, Beijing, Guangzhou, Foshan, Nanjing, Shanghai, Tianjin and Hong Kong. Guosen Securities provides sales and trading, investment banking, research, asset management, private equity, and other financial services with both institutional and retail clients in mainland China and Hong Kong. The company's heritage can be traced back to 1989, when it was originated from the Shenzhen International Trust and Investment Securities Business Division. In 1996, it became an independent corporation and was renamed as Guosen Securities. In 2011, Guosen Securities gained the second largest market share of 8.8 percent in domestic equity offerings and the 18th market share of 0.9 percent in global equity offerings. Website: www.guosen.com.cn
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia
Tel: +86-28-8551-6696 (Chengdu, China)
Address:
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China
